Driven by collaboration revenue/breakthrough in innovative drug business, Hansoh's 2023 results beat expectations. But Ameile’s future growth could slow. Upfront payment from GSK is expected in 2024.
What is covered in the Full Insight:
Hansoh's 2023 Performance
importance of Ameile to Hansoh
Competition and Challenges faced by Hansoh
Hansoh and Innovation
Hansoh's Outlook for 2024
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.